salbutamol and isoprenaline increased cardiac output. With isoprenaline this was achieved by an increase in heart rate. The increased cardiac output after salbutamol resulted from increased stroke volume without marked chronotropy. It was almost certainly P2 in origin because it depended on increased venous return caused by dilatation of peripheral blood vessels. Similar cardiovascular effects in man would make salbutamol a possibly useful drug for the treatment of cardiogenic shock. Discuission The results show that isoprenaline does not differentiate between P-receptors in different tissues and the selectivity of orciprenaline is small. In contrast, salbutamol is clearly more active on bronchial smooth muscle than on cardiac muscle; it is also longer acting than isoprenaline. Terbutaline is rather like salbutamol but is less active. Trimetoquinol is not obviously selective in its in vivo actions.
Lands and his colleagues were the first to propose a P1, P2 classification of P-adrenoceptors but it is interesting to see that evidence for this classification was already present in the literature, particularly in the work of Furchgott (1967) who showed that the sensitivity of tracheal muscle and heart muscle to the natural transmitters, noradrenaline and adrenaline, were significantly different. The results given in this paper are even better evidence for the Lands proposals. P1and P2-receptors must obviously be chemically different. It is most likely that the P2-receptor allows an additional ordering interaction with the N-methyl substituent of adrenaline. The interactions of the receptors with selective synthetic agonists such as salbutamol must be more varied and could well involve exo-receptor sites. Those interactions at P2 sites must be ordering and thus cause agonistic responses; any interactions which occur at P1 sites must be disordering and lead to partial agonistic or blocking effects. The concept of the adrenergic receptor was proposed by Langley (1905) and substantiated by Dale (1906) . Dale showed that adrenaline contracted vascular, cardiac, splenic and uterine muscle, but relaxed biliary and intestinal smooth muscle. In animals previously given the alkaloid ergot, the action of adrenaline was reversed in that it relaxed splenic, uterine and vascular smooth muscle, but its action on biliary and intestinal muscle was unchanged. The stimulant actions of adrenaline on the heart, piloerector muscles and dilator iridis were prevented.
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In current terminology, these results would be interpreted as showing that adrenaline has astimulant actions on splenic and vascular muscle which is converted to a P inhibitory response in the presence of the a blocking agent, ergot. The reversal of adrenaline effects is due to its action on P-receptors, which can only be observed in the presence of a-receptor blockade. Ergot has predominantly a-blocking actions and, in high doses, some P-receptor blocking action on the heart. The first specific P-receptor blocking drug to be discovered was dichloroisoprenaline (DCI) (Powell & Slater 1958) . This compound was soon followed by pronethalol (Black & Stevenson 1962) , and propranolol (Black et al. 1965) . Currently, more than 20 pharmaceutical companies are synthesizing and testing a wide variety of compounds for P-adrenergic blocking activity. A P-blocking drug may be defined as a competitive specific antagonist at the P-receptor (Barrett & Fitzgerald 1968) . A competitive antagonist may be defined as one which moves the dose-response curve for agonist/antagonist interaction to the right without changing its slope. Specific antagonism implies blockade of only the adrenoceptive site. Thus Dale (1906) showed that ergot, whilst blocking the action of adrenaline on vascular muscle, did not prevent vasoconstriction by pituitrin. Similarly, propranolol and practolol block the positive inotropic actions of the specific P-stimulant isoprenaline, but do not block the actions of acetylstrophanthidin, calcium or glucagon, nor do they antagonize the actions of histamine or acetylcholine.
Once the first P-receptor blocking drugs had been discovered, research concentrated on finding compounds that were not only specific but also more potent and more selective. Selectivity, as opposed to specificity, of P-receptor blockade implies that an agent will, at a certain dose, block fl-receptor sites in some tissues but not in others. Thus, selectivity tends to be relative rather than absolute and is dose dependent. The first fblocking drug, DCI, antagonizes P-receptors in all tissues in which it has been studied (Moran 1966) . DCI also has mild ,8-stimulant actions in that it will increase heart rate and raise circulating levels of free fatty acids, though it still antagonizes the action of isoprenaline. Pronethalol was developed and studied in man because it had much less fl-stimulant activity than DCI (Barrett & Carter 1970) . Propranolol replaced pronethalol because it had no ,B-stimulant activity, was much more potent and was better tolerated. Extensive clinical studies with propranolol show that it is of value in angina pectoris, cardiac arrhythmias, hypertension, phaochromocytoma, some forms of congenital heart disease and thyrotoxicosis (Dollery et al. 1969 , Fitzgerald 1969 .
Selective Blockade
The fl-receptors that are now thought to be of clinical importance are: (1) The cardiac receptors subserving rate, force and conduction velocity.
(2) Receptors in lung and vascular smooth muscle.
(3) Beta-receptors associated with lipolysis and glycogenolysis.
The clinical importance of blockade of fireceptors in tissues such as bladder, gut, uterus and eye remains to be proven. The beneficial effects of propranolol in the clinical disorders described arise from its ability to block cardiac f-receptors. Blockade of vascular and metabolic fl-receptors is not known to be clinically beneficial. Blockade of fl-receptors in bronchial smooth muscle can be harmful in subjects suffering from obstructive airways disease (McNeil 1971) .
The first selective f-blocking drugs described were a-methyl substituted arylethanolamines. These are the 1-(3,5-dimethoxyphenyl)-2-aminopropanol derivatives, butoxamine and isopropylmethoxamine (Burns et al. 1964 , Salvador & April 1965 , and the 3,4-dimethylphenyl (H35/59), 4-methylphenyl (H35/25), and 3,4-dichlorophenyl analogues (Van Deripe et al. 1964, Van Deripe & Moran 1965 ). These compounds antagonize the action of isoprenaline on vascular smooth muscle in dogs at doses which do not block its cardiac effects. Butoxamine, the only one studied in man, blocks catecholamine-induced lipolysis, but also blocks catecholamine effects on the heart in conscious dogs and man (Burns et al. 1967 , Maxwell et al. 1967 , so its selectivity of action is questionable. Butoxamine also blocks bronchial and uterine f-receptors in vitro (Levy & Wilkenfeld 1970) , but not intestinal fl-receptors. The 4-methylphenyl analogue (H35/25) has a similar spectrum of effects, but its action on lipolysis and bronchial muscle has not been reported.
The first cardioselective fl-blocker, practolol, was described in 1968 (Dunlop & Shanks 1968 ). The term cardioselective means that such compounds block the cardiac fl-receptor at doses which do not effectively block fl-receptors in other tissues. This selectivity is relative in that, if the dose of cardioselective fl-blocking drug is increased sufficiently, it will finally block f-receptors in other tissues. More recently, three other cardioselective fl-blocking drugs have been described. Two of them are positional isomers of the nonselective fl-blocking drugs oxprenolol and alprenolol which have, respectively, an allyloxy and an alyl substituent in the ortho position of the benzene ring. The corresponding para substituted compounds have a relatively greater blocking action on the heart than on peripheral vascular fl-receptors (Ablad et al. 1970) .These compounds have not been studied in man. The other example is M & B 17803A, which is cardioselective in animals, though there is conflicting evidence at present concerning its cardioselectivity in man (Briant et al. 1971) .
Clinical studies with nonselective fl-blockers such as propranolol have indicated that cardiac fl-blockade is the desirable feature, whereas the blockade of fl-receptors in other tissues is not of proven value (Fitzgerald 1969) . The feature of particular clinical significance in a fl-blocking drug is lack of effect on bronchial smooth muscle. The cardioselectivity of practolol in this sense, in man, has been amply proven (McDonald & McNeil 1968 , Powles et al. 1969 , Palmer et al. 1969 , Turner et al. 1971 , Hedges & Turner 1971 . There is no evidence that alprenolol or oxprenolol is cardioselective in man, though several authors misleadingly state that this is so (Leishman et al. 1970 , Stephen et al. 1971 , Beumer 1968 ). Studies of the effects of practolol, administered by aerosol, on lung function are of little guidance, since (a) fi-adrenergic blocking drugs are not administered by this route in clinical practice, (b) selectivity is relative and therefore it is meaningless to administer a cardioselective f-blocker directly into the lung (Bernecker & Roetscher 1970) , and (c) because of the great variability between susceptible subjects, it is essential that the response of each to a nonselective fl-blocker is determined initially. The only meaningful studies are those of McDonald & McNeil (1968) and Frullani et al. (1969) .
Practolol has been shown to block cardiac receptors much more effectively than vascular receptors in animals and man (Brick et al. 1968 , Harrison & Turner 1969 , Briant et al. 1971 . The action of practolol on coronary blood vessels depends to some extent on the agonist used.
Where isoprenaline is used to dilate coronary vessels and to increase myocardial work, the latter effect is prevented by practolol, but not the former (Ross & Jorgensen 1970 , Barrett 1971 , Parratt & Wadsworth 1970 , Bussman et al. 1970 . The cardiac effects of noradrenaline or stimulation of the cardio-accelerator nerve, when either of these is used, are blocked and their initial action in reducing coronary flow is unaffected or potentiated by practolol (McRaven et al. 1971 , Adam et al. 1970 , Lucchesi & Hodgeman 1971 . The result of the action of practolol in reducing myocardial work, but possibly potentiating the a actions of endogenous catecholamines on coronary flow in man, is undetermined.
Other Pharmacological Properties
The earlier nonselective p-blocking drugs such as DCI, propranolol, alprenolol and oxprenolol, possess significant membrane-stabilizing properties, also referred to as 'local anaesthetic' because of the effects of these drugs on nerve conduction, or 'quinidine-like' because of their effects on the transmembrane action potential of the rabbit atrium (Morales-Aguilera & Vaughan-Williams 1965). Practolol does not have local anesthetic activity (Barrett 1971) and the significance in vivo of its reported effects on transmembrane action potential in vitro (Papp & Vaughan-Williams 1969) has been questioned (Fitzgerald et al. 1972) . Certainly practolol in plasma concentrations of 58 s&g/ml is free of membrane-stabilizing properties in vivo.
Studies in man suggest that the membranestabilizing action of propranolol does not play a role in its anti-anginal (Wilson et al. 1969 ), antihypertensive (Waal-Manning 1970 or antiarrhythmic effects (Coltart et al. 1971 , Linko et al. 1968 ). The slight anti-arrhythmic effect seen with high doses of the non-p-blocking dextro isomers of propranolol and alprenolol (Smithers et al. 1971) is probably due to the demonstrable, albeit very low , p-blocking activity of these compounds. Arrhythmias which are sensitive to P-blocking drugs appear to respond to very low doses, and this may explain the response to these dextro isomers. Despite this, reviewers continue to suggest that membrane-stabilizing action of pblockers has clinical relevance (Brunner et al. 1971 , Gray 1971 , Stephen et al. 1971 .
Practolol, unlike propranolol, possesses partial agonist (i.e. intrinsic sympathomimetic) activity (Barrett & Carter 1970) . The clinical significance of this property is not clear at present, though there is evidence that p-blocking drugs with this property do not reduce cardiac function as much as those without it (Johnsson 1969 , Jewitt et al. 1970 . The critical question that remains unanswered is whether such drugs are also as effective in conditions such as angina pectoris, where therapeutic effectiveness relates to reduced cardiac work. The study, in man, of a compound similar to practolol, but without partial agonist properties, might resolve this question. 43, 320 Turner P, Burman J, Hicks D C, Charrington N K, MacKinnon J, Waller T & Woolnough M (1971) Archives internationales de pharmacodynamie et de thdrapie 191, 104 Van Deripe D R, Ablad B & Moran N C (1964) Dr Brittain replied that in man salbutamol did not depress arterial oxygen tension when the airway obstruction was relieved.
Dr P J Bourdillon (Hammersmith) asked Dr Fitzgerald to comment on the apparent synergistic action of calcium chloride and practolol on the left ventricular dp/dt of the dog. Dr Fitzgerald replied that he had no explanation for the apparent potentiation of the inotropic response to calcium by practolol.
Professor J W Dundee (Belfast) wondered whether, in view of the effect of salbutamol on muscle twitch, it would interact with muscle relaxants in the anaesthetized subject. For clinical use in man a parenteral form would be needed, which maight cause arrhythmias with halothane anw,sthesia. He felt it would be interesting to know if muscle tremors induced by isoprenaline or salbutamol were controlled by practolol or propranolol. While atropine was an effective antidote to practolol, in view of the duration of the blocking drug it might have to be repeated; calcium chloride would also seem to be a more useful antidote than the lactate. Dr Fitzgerald thought that propranolol was more effective than practolol in antagonizing catecholamine-induced muscle tremors. Dr Brittain commented that muscle tremors did not occur if salbutamol was taken by aerosol administration. If it was given by mouth, however, a small percentage of patients would develop tremor. This tremor was mediated through ,Breceptors and could be blocked by p-blockers.
Dr F S Keddie (Plymouth) asked what was the duration of action of propranolol and practolol. Dr Fitzgerald stated that the duration of action of propranolol given orally was between two and four hours, whereas that of practolol was ten hours (Fitzgerald J D & ScAles B, 1968, International 
